QLT Inc. Receives Fast Track Designations for QLT091001 to Treat Both Leber Congenital Amaurosis and Retinitis Pigmentosa

VANCOUVER, British Columbia, Sept. 14, 2011 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) today announced the Company's oral synthetic retinoid for retinal diseases, QLT091001, has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the treatment of Leber Congenital Amaurosis (LCA) due to inherited mutations in LRAT and RPE65 genes and for the treatment of autosomal recessive Retinitis Pigmentosa (RP) due to inherited mutations in LRAT and RPE65 genes.

Back to news